Traws Pharma initiated with a Buy at Ladenburg

Traws Pharma Completes Enrollment in Phase 2 Ratutrelvir COVID-19 Study

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files IND Application for Tivoxavir Marboxil Influenza Therapy

Traws Pharma Inc: Full Study Enrollment Expected in January 2026

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (Ind) Application for Influenza Therapy, and Provides Updated Results From the Ongoing Clinical Study of Ratutrelvir in Paxlovid®-Eligible and Ineligible Covid-19 Patients

Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients

Traws Pharma Inc: Ratutrelvir Shows a Differentiated Profile Versus Paxlovid™ With Fewer Adverse Events and No Viral Rebounds

Traws Pharma Inc: Final Data Analysis to Be Reported in January 2026

Traws Pharma Reports Positive Interim Clinical Data With Ratutrelvir Versus Paxlovid™, Shows Activity in Paxlovid-Ineligible Covid-19 Patients

Traws Pharma Grants Stock Options and RSUs to Executive Team

HC Wainwright Initiates Traws Pharma at Buy With $8 Price Target

Traws Pharma Initiated at Buy by HC Wainwright & Co.

Traws Pharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

Traws Pharma Inc. Held Annual Shareholder Meeting

Traws Pharma Q3 EPS $(0.34) Up From $(8.81) YoY

Traws Pharma posts $4.0 million net loss on zero revenue for Q3 2025

Traws Pharma Inc: Q3 EPS $-0.34

Press Release: Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

Traws Pharma Extends CMC Services Contract With ChemDiv for Ratutrelvir Clinical Development